Navigation Links
Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc.
Date:7/14/2014

San Francisco, Calif., July 14, 2014 /PRNewswire/ -- Synthetic biology company Pareto Biotechnologies today announces a technology partnership with global bioengineering leader DNA2.0, enabling Pareto to further develop its technology for quick-to-market products.

The integration of Pareto's rational-based design approach and DNA2.0's machine learning optimization technologies, such as ProteinGPS™ and GeneGPS™, is drastically speeding up the process of engineering proteins in the Pareto pipeline. Specifically, Pareto will merge its novel synthetic biology platform with DNA2.0's ProteinGPS™ engineering technology, to identify and quantify genetic mutations to be incorporated into iterative rounds of improved synthetic genes. The tool rapidly generates proteins with improved characteristics.

"Rational-based design has been the core of my life's work. The marriage of Pareto's novel platform with DNA2.0's engineering expertise will create fantastic opportunities for enhancing enzymes for the production of Pareto products," said Dr. Joseph Noel, Salk Institute for Biological Studies Professor and Chairman of Pareto Biotechnologies' Scientific Advisory Board.

Pareto's CEO, Jamie Bacher, continued, "Our deep understanding of the structures of these classes of enzymes, along with a statistical optimization algorithm from DNA2.0 gets us the best of both worlds: rational design and robust enzyme improvement. Through our relationship with DNA2.0, we'll be able to generate completely novel molecules with applicability to flavors and fragrances, cosmetics, and therapeutics."

The broad applicability of this combined approach enables a progressive application of the technology along the value chain, as a practical demonstration of the power of market-driven research and development efforts – a.k.a. "Synthetic Biology 2.0." Pareto will leverage DNA2.0's specific technologies to increase the efficacy of its own platform to generate flavors, fragrances and cosmetics with improved and novel properties. As the technology is further developed, it will also enhance drug discovery platforms, as well as the generation of industrial chemicals.

"Our patented bioengineering approaches, especially ProteinGPS™ and GeneGPS™, have been validated by many scientific publications and successful partners. Recently we published a seminal ProteinGPS paper in ACS Synthetic Biology. The technology allows the researcher to engineer any biological function using only a few hundred samples. We are delighted to partner with Pareto and Dr. Joe Noel in their exciting endeavor to ignite the molecular revolution," said Claes Gustafsson, DNA2.0's Chief Commercial Officer.

About Pareto Biotechnologies:
Pareto Biotechnologies is a synthetic biology startup that is poised to lead the movement towards a bio-based economy. Pareto's platform fully leverages its dominant IP position in polyketide pathways, combining structurally-guided enzyme design and synthetic biology to develop a platform for designer molecules with broad applicability: cosmetics, flavors, fragrances, therapeutics, industrial commodity chemicals, and chemical intermediates. Learn More About Pareto Biotechnologies.

About DNA2.0:
DNA2.0 is the leading bioengineering solutions provider, offering an integrated pipeline of solutions, including gene design, optimization, synthesis, and platforms for protein and strain engineering. DNA2.0 explores novel applications for synthetic genes and the synergy between efficient gene design and protein optimization technologies. DNA2.0's tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. Learn More About DNA2.0.

Media Contact:
Kristen Caron
Kristen@7SecondStrategies.com 
978-407-9283


'/>"/>
SOURCE Pareto Biotechnologies
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. HedgePath Pharmaceuticals, Inc. Completes Reorganization Plan with Commonwealth Biotechnologies
2. Medical Marijuana Inc. Portfolio Company CanChew BioTechnologies Inc. Announces Final Three Days for Market Survey and Free Product Trial Registration
3. Lifeline Biotechnologies Receives Third Software Patent
4. Lifeline Biotechnologies First Warning Systems
5. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
6. ISSI Announces Fiscal 2014 Third Quarter Conference Call
7. CVS Caremark Corporation Announces Quarterly Dividend
8. Sono-Tek Announces Third Quarter Results
9. Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering
10. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
11. Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition of the ... their offering. ... The ablation device global market is expected to grow at high ... Ablation is the minimally invasive therapeutic tissue excision procedure used ... removal, to the removal of abnormally conducting cardiac tissue in atrial ...
(Date:3/29/2017)... , March 29, 2017  Spiral Therapeutics, ... agreement with Bionure Farma, S.L. for the worldwide ... to BN119 in the field of otolaryngology for ... sales-based royalties. The agreement provides Spiral with ... with a differentiated product profile. Under the terms ...
(Date:3/29/2017)... 2017   Royal Philips (NYSE: PHG, ... and PathAI, a company that develops artificial intelligence ... to develop solutions that improve the precision and ... diseases. The partnership aims to build deep learning ... artificial intelligence to be applied to massive pathology ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 bottles ... AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while doing ... an over the counter heart healthy drink, can reduce Arterial Plaque, Lower Blood ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... growing as it continues developing an ANSI-approved, consensus-based American National Standard for ... plans to publish the first ANSI-approved GMP standard for dietary supplements this ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an ... 20, 2017, at 1:00 PM ET. A recording of the webinar will also be ... Series. , Home health and hospice companies are still popular targets for healthcare investors. ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who ... at Intercontinental Time Square, New York. , The program will be led ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
Breaking Medicine News(10 mins):